MAGELLAN LONGEVITY
HomeResearchStudy library › Citrus polyphenol hesperidin stimulates nitric oxide production…
Study summary · Cardiovascular & vascular aging

Does hesperetin stimulate nitric oxide production from vascular endothelium, and does oral hesperidin therapy improve endothelial function and reduce inflammatory markers in individuals with metabolic syndrome?

In one paragraph

Hesperidin Citrus Flavonoid, a randomized crossover trial in 24 individuals (J Clin Endocrinol Metab 2011, PMID 21346065) — in the clinical study, hesperidin treatment increased flow-mediated dilation (10.26% vs. 7.78% with placebo) and reduced concentrations of high-sensitivity C-reactive protein, serum amyloid A protein, and soluble E-selectin. The clinical trial was exploratory with a small sample size (n=24) and a relatively short intervention period (3 weeks).

Source: J Clin Endocrinol Metab 2011, PMID 21346065 ↗ · Research map · How Magellan grades evidence · evidence confidence: high

J Clin Endocrinol Metab · 2011 · PMID 21346065 · DOI 10.1210/jc.2010-2879

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

Hesperidin improves blood vessel function and reduces inflammation in people with metabolic syndrome, potentially through its metabolite hesperetin stimulating nitric oxide production.

The question

Does hesperetin stimulate nitric oxide production from vascular endothelium, and does oral hesperidin therapy improve endothelial function and reduce inflammatory markers in individuals with metabolic syndrome?

What they tested

Hesperetin, a citrus flavonoid metabolite, may stimulate nitric oxide production and improve vascular function, while oral hesperidin therapy may improve endothelial function and reduce inflammatory markers in subjects with metabolic syndrome.

How they did it

Cellular mechanisms of hesperetin were studied in bovine aortic endothelial cells (BAEC) in primary culture. A randomized, placebo-controlled, double-blind, crossover trial was conducted in 24 individuals with metabolic syndrome, who received oral hesperidin (500 mg once daily for 3 weeks) or placebo. Brachial artery flow-mediated dilation and circulating inflammatory biomarkers were measured.

What they found

In BAEC, hesperetin acutely stimulated phosphorylation of Src, Akt, AMP kinase, and endothelial NO synthase, leading to NO production, which required H2O2. Hesperetin pretreatment reduced monocyte adhesion to BAEC and vascular cell adhesion molecule-1 expression induced by TNF-α. In the clinical study, hesperidin treatment increased flow-mediated dilation (10.26% vs. 7.78% with placebo) and reduced concentrations of high-sensitivity C-reactive protein, serum amyloid A protein, and soluble E-selectin.

Flow-Mediated Dilation (FMD) in Metabolic Syndrome Patients
Values shown: FMD (%)
Placebo7.78
Hesperidin10.26

Flow-mediated dilation was significantly higher after hesperidin treatment compared to placebo in individuals with metabolic syndrome.

What it means

Hesperetin has vasculoprotective actions, including stimulating NO production and reducing inflammation in endothelial cells. Oral hesperidin treatment improves endothelial dysfunction and reduces circulating inflammatory markers in individuals with metabolic syndrome.

Limitations

The clinical trial was exploratory with a small sample size (n=24) and a relatively short intervention period (3 weeks).

“hesperidin increased flow-mediated dilation and reduced circulating inflammatory biomarkers”— from the published abstract, J Clin Endocrinol Metab 2011

The paper at a glance

TitleCitrus polyphenol hesperidin stimulates nitric oxide production while improving endothelial function and reducing inflammatory markers in metabolic syndrome
JournalJ Clin Endocrinol Metab
Year2011
PMID21346065 ↗
DOI10.1210/jc.2010-2879 ↗
TopicCardiovascular & vascular aging

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Where Magellan uses this paper

This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.

Hesperidin Citrus Flavonoid

In human trials, hesperidin or hesperidin-rich orange juice has improved endothelial function and postprandial microvascular reactivity, modestly lowered blood pressure in some studies — including a 159-person trial showing dose-dependent systolic and pulse-pressure reductions with sustained intake — and reduced…

Hesperidin Citrus Flavonoid

Hesperidin is a flavanone glycoside (a citrus bioflavonoid) found abundantly in oranges, lemons, and…

Check price on Amazon ↗

Research describes the compound or intervention studied. It is not a claim about any specific product.

Molecules & mechanisms in this paper

Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). Does hesperetin stimulate nitric oxide production from vascular endothelium, and does oral hesperidin therapy improve endothelial function and reduce inflammatory markers in individuals with metabolic syndrome? [Plain-English summary of J Clin Endocrinol Metab 2011, PMID 21346065, DOI 10.1210/jc.2010-2879]. Magellan Longevity. https://magellanlongevity.com/study/d21346065.html
BibTeX
@misc{magellan_d21346065, title = {Does hesperetin stimulate nitric oxide production from vascular endothelium, and does oral hesperidin therapy improve endothelial function and reduce inflammatory markers in individuals with metabolic syndrome?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/d21346065.html}}, note = {Plain-English summary of PubMed PMID 21346065; DOI 10.1210/jc.2010-2879; J Clin Endocrinol Metab 2011. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/d21346065.html

Related studies in the Magellan library

All 67 Magellan summaries on cardiovascular & vascular aging →

How this summary was made. Every section above restates what the published abstract of PMID 21346065 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.